Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

Cowen & Co. 42nd Annual Health Care Conference

Format: Fireside Chat

Date: Monday, March 7, 2022

Time: 1:30 p.m. ET

Oppenheimer 32nd Annual Healthcare Conference

Format: Company Presentation

Date: Thursday, March 17, 2022

Time: 2:40 p.m. ET

A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the website for 90 days.

About Impel NeuroPharma

Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD^®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

Contact:

Media Relations:

Melyssa Weible

Elixir Health Public Relations

Phone: (1) 201-723-5805

Email: mweible@elixirhealthpr.com 

Investor Relations

Christina Tartaglia

Stern Investor Relations

Phone: 212-362-1200

Email: christina.tartaglia@sternir.com